Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Elisoa Ratsima is active.

Publication


Featured researches published by Elisoa Ratsima.


Journal of Virological Methods | 2008

Evaluation of the performance of four rapid tests for detection of hepatitis B surface antigen in Antananarivo, Madagascar

Frédérique Randrianirina; Jean-François Carod; Elisoa Ratsima; Jean-Baptiste Chrétien; Vincent Richard; Antoine Talarmin

Four rapid immunochromatographic assays--Determine HBsAg, Virucheck HBsAg, Cypress HBsAg Dipstick and Hexagon HBsAg--for human hepatitis B surface antigen (HBsAg) detection in human serum were evaluated. A collection of reference serum samples (91 HBsAg positive and 109 HBsAg negative) stored at -80 degrees C was used. Sensitivity and positive predictive value (PPV) exceeded 95%, and specificity and negative predictive value (NPV) exceeded 96% for all tests. The Determine HBsAg test performed best in this study, with a sensitivity of 97.8%, a specificity and PPV of 100%, a NPV of 98.2% and an accuracy rate of 99.0%. However, the differences between the tests were not significant. Other factors should therefore also be taken into account by the Ministry of Health in its decision to recommend a particular test: price, availability, delivery time and feasibility of whole-blood testing. The Determine test appears to be the most suitable for Madagascar, based on all these criteria. The use of this test, despite its lower sensitivity, could prevent blood-borne transmission of hepatitis B virus (HBV) in areas with limited resources.


Annals of Clinical Microbiology and Antimicrobials | 2010

Dissemination of multidrug resistant Acinetobacter baumannii in various hospitals of Antananarivo Madagascar

Tahiry S Andriamanantena; Elisoa Ratsima; Hanitra Clara Rakotonirina; Frédérique Randrianirina; Lovasoa Ramparany; Jean-François Carod; Vincent Richard; Antoine Talarmin

This study reports the dissemination of multidrug-resistant (MDR) OXA-23-producing Acinetobacter baumannii clones in hospitals in Antananarivo, Madagascar. A total of 53 carbapenem-resistant A. baumannii isolates were obtained from September 2006 to March 2009 in five hospitals. These resistant strains represent 44% of all A. baumannii isolates. The double disk synergy test was performed to screen for production of metallo-beta-lactamases. Polymerase chain reaction (PCR) and DNA sequencing were performed for the detection of bla(AmpC), bla(OXA-51),bla(OXA-23), bla(OXA-24), bla(IMP), bla(VIM). The presence of the insertion sequence ISAba1 relative to bla OXA-23 and bla OXA-51 was assessed by PCR. Isolates were typed by Rep-PCR. All the isolates were MDR and produced the OXA-23 carbapenemase, which was confirmed by sequencing. PCR analysis for AmpC and OXA-51 gave positive results for all strains studied. No isolates produced metallo-beta-lactamases. In all isolates ISAba1 laid upstream of bla OXA-23. The A. baumannii isolates were separated into two genotypes; genotype A had a higher prevalence (41 strains) than genotype B (12 strains). Genotype A was present in four hospitals, whilst genotype B had spread in two hospitals. The high frequency of MDR OXA-23-producing A. baumannii in various hospitals in Antananarivo is curious since carbapenems are not available in Madagascar, but it emphasises the need for infection control procedures and strict adherence to them to prevent the spread of these resistant organisms in Antananarivo and also the need to control the use of carbapenems in the future.


Annals of Clinical Microbiology and Antimicrobials | 2007

In vitro activities of 18 antimicrobial agents against Staphylococcus aureus isolates from the Institut Pasteur of Madagascar

Frédérique Randrianirina; Jean-Louis Soares; Elisoa Ratsima; Jean-François Carod; Patrice Combe; Pierre Grosjean; Vincent Richard; Antoine Talarmin

BackgroundStaphylococcus aureus, one of the most frequently isolated pathogens in both hospitals and the community, has been particularly efficient at developing resistance to antimicrobial agents. In developed countries, as methicillin-resistant S. aureus (MRSA) has prevailed and, furthermore, as S. aureus with reduced susceptibility to vancomycin has emerged, the therapeutic options for the treatment of S. aureus infections have become limited. In developing countries and especially African countries very little is known concerning the resistance of S. aureus to antibiotics. In Madagascar no data exist concerning this resistance.ObjectiveTo update the current status of antibiotic resistance of S. aureus in Antananarivo, Madagascar.MethodsClinical S. aureus isolates were collected from patients at the Institut Pasteur of Madagascar from January 2001 to December 2005. Susceptibility tests with 18 antibiotics were performed by the disk diffusion method.ResultsAmong a total of 574 isolates, 506 were from community-acquired infections and 68 from nosocomial infections. There was no significant difference in the methicillin resistance rate between community-acquired strains (33 of 506; 6.5%) and nosocomial strains (3 of 68, 4.4%). Many MRSA isolates were resistant to multiple classes of antibiotics. Resistance to tetracyclin, trimethoprim-sulfamethoxazole and erythromycin was more common. Among MRSA isolates resistance rates to rifampicin, fusidic acid, gentamicin and ciprofloxacin were lower than that observed with other drugs easily available in Madagascar. No isolates were resistant to glycopeptides.ConclusionThe rate of methicillin-resistant S. aureus is not different between community-acquired and nosocomial infections and is still rather low in Madagascar.


Sexually Transmitted Diseases | 2008

Antimicrobial susceptibility of Neisseria gonorrhoeae strains isolated in 2004-2006 in Bangui, Central African Republic; Yaoundé, Cameroon; Antananarivo, Madagascar; and Ho Chi Minh Ville and Nha Trang, Vietnam.

Van Cao; Elisoa Ratsima; Doan Van Tri; Raymond Bercion; Marie-Christine Fonkoua; Vincent Richard; Antoine Talarmin

Goal: To investigate the in vitro antimicrobial susceptibility of Neisseria gonorrhoeae strains isolated in 2004 and 2005 in Bangui, Central African Republic; Yaoundé, Cameroon; Antananarivo, Madagascar; and Ho Chi Minh Ville and Nha Trang, Vietnam. Study Design: Antimicrobial susceptibility testing was performed by both disk diffusion and agar dilution methods according to Clinical and Laboratory Standards Institute (CLSI) recommendations. Minimum inhibitory concentrations (MICs) to 5 antimicrobials (penicillin G, ceftriaxone, ciprofloxacin, spectinomycin, and tetracycline) were determined when feasible. Penicillinase-producing N. gonorrhoeae (PPNG) was analyzed by the paper acidometric method (nitrocefin test). Results: Thirty N. gonorrhoeae isolates from Bangui could be studied, 79 from Yaoundé, 126 from Antananarivo, 56 from Nha Trang, and 126 from Ho Chi Minh Ville in 2004 and 2005. Unfortunately, because of problems of electricity supply, no strains could be recovered for the determination of MICs in Yaoundé, and only 68 strains could be tested in Antananarivo and 121 in Ho Chi Minh Ville. Patterns of resistance were similar in Antananarivo, Bangui, and Yaoundé but different from those observed in Vietnam. Ciprofloxacin was highly effective in Africa, but nearly all strains in Vietnam were resistant to this drug. Overall, ceftriaxon and spectinomycin were the best antibiotics, with one strain resistant to spectinomycin in Antananrivo and one strain resistant to ceftriaxon in Ho Chi Minh Ville. Conclusions: Ciprofloxacin remains highly efficient in Madagascar and Central Africa, ceftriaxone and spectinomycin should be used as the first-line antimicrobial agents in treating gonorrhea in Vietnam.


PLOS ONE | 2013

Outcome Risk Factors during Respiratory Infections in a Paediatric Ward in Antananarivo, Madagascar 2010–2012

Soatiana Rajatonirina; Norosoa Harline Razanajatovo; Elisoa Ratsima; Arnaud Orelle; Rila Ratovoson; Zo Zafitsara Andrianirina; Todisoa Andriatahina; Lovasoa Ramparany; Perlinot Herindrainy; Frédérique Randrianirina; Jean-Michel Heraud; Vincent Richard

Background Acute respiratory infections are a leading cause of infectious disease-related morbidity, hospitalisation and mortality among children worldwide, and particularly in developing countries. In these low-income countries, most patients with acute respiratory infection (ARI), whether it is mild or severe, are still treated empirically. The aim of the study was to evaluate the risk factors associated with the evolution and outcome of respiratory illnesses in patients aged under 5 years old. Materials and Methods We conducted a prospective study in a paediatric ward in Antananarivo from November 2010 to July 2012 including patients under 5 years old suffering from respiratory infections. We collected demographic, socio-economic, clinical and epidemiological data, and samples for laboratory analysis. Deaths, rapid progression to respiratory distress during hospitalisation, and hospitalisation for more than 10 days were considered as severe outcomes. We used multivariate analysis to study the effects of co-infections. Results From November 2010 to July 2012, a total of 290 patients were enrolled. Co-infection was found in 192 patients (70%). Co-infections were more frequent in children under 36 months, with a significant difference for the 19–24 month-old group (OR: 8.0). Sixty-nine percent (230/290) of the patients recovered fully and without any severe outcome during hospitalisation; the outcome was scored as severe for 60 children and nine patients (3%) died. Risk factors significantly associated with worsening evolution during hospitalisation (severe outcome) were admission at age under 6 months (OR = 5.3), comorbidity (OR = 4.6) and low household income (OR = 4.1). Conclusion Co-mordidity, low-income and age under 6 months increase the risk of severe outcome for children infected by numerous respiratory pathogens. These results highlight the need for implementation of targeted public health policy to reduce the contribution of respiratory diseases to childhood morbidity and mortality in low income countries.


Pediatric Infectious Disease Journal | 2017

Prevalence of Mycoplasma pneumoniae Infection in Malagasy Children

Lova Ravelomanana; Naïm Bouazza; Mbola Rakotomahefa; André Zo Andrianirina; Annick Lalaina Robinson; Honoré Raobidjaona; Rabezanahary Andriamihaja; Nadjet Benhaddou; Frédérique Randrianirina; Elisoa Ratsima; Patrick Imbert; Josette Raymond

Background: Childhood community-acquired pneumonia is a leading cause of childhood morbidity in low-income countries. The etiologic agents are usually Staphylococcus aureus, Streptococcus pneumoniae and Mycoplasma pneumoniae. M. pneumoniae was recognized as a cofactor in asthmatic disease. High asthma prevalence was reported in Madagascar. Our aim was to clarify the prevalence of M. pneumoniae infection in this country and its relationship with asthma. Methods: A prospective study was conducted in 351 children (from 2 to 16 years of age) from January 2012 to December 2014. According to the clinical symptoms, children were enrolled in 3 groups: “control group” (CG, n = 106), “asthma group” (n = 129) and “pneumonia group” (n = 116). The IgG and IgM M. pneumoniae status was evaluated by an enzyme-linked immunosorbent assay. Clinical signs of infection, socioeconomic data and antimicrobial treatment were recorded. Results: The overall prevalence of M. pneumoniae infection was 18.2%. The multivariate analysis demonstrated that M. pneumoniae infection was significantly more frequent in the CG [pneumonia group vs. CG: odds ratio = 0.45 (0.21–0.91), P = 0.037 and asthma group vs. CG: odds ratio = 0.39 (0.18–0.87), P = 0.021]. The C-reactive protein value was significantly higher in children with M. pneumonia–positive serology (85 vs. 61 mg/L, P = 0.03). Of note, 99 (41%) children received antibiotics before attending. Conclusions: We report a prevalence of 18.2% for M. pneumoniae infection in children in Madagascar. The prevalence of M. pneumoniae infection was higher in the control patients than in asthmatic ones.


Journal of Antimicrobial Chemotherapy | 2006

Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in Antananarivo, Madagascar

Frédérique Randrianirina; Jean-Louis Soares; Jean-François Carod; Elisoa Ratsima; Vincent Thonnier; Patrice Combe; Pierre Grosjean; Antoine Talarmin


BMC Infectious Diseases | 2014

Antimicrobial resistance of bacterial enteropathogens isolated from stools in Madagascar

Frédérique Randrianirina; Elisoa Ratsima; Lova Ramparany; Rindra Vatosoa Randremanana; Hanitra Clara Rakotonirina; Tahiry S Andriamanantena; Fanjasoa Rakotomanana; Soatiana Rajatonirina; Vincent Richard; Antoine Talarmin


BMC Infectious Diseases | 2016

Neonatal infections with multidrug-resistant ESBL-producing E. cloacae and K. pneumoniae in Neonatal Units of two different Hospitals in Antananarivo, Madagascar

Thierry Naas; Gaelle Cuzon; A. L. Robinson; Z. Andrianirina; P. Imbert; Elisoa Ratsima; Z. N. Ranosiarisoa; Patrice Nordmann; Josette Raymond


Pediatric Infectious Disease Journal | 2018

Epidemiology of Early-Onset Bacterial Neonatal Infections in Madagascar

Zoly Nantenaina Ranosiarisoa; Sélim El Harrif; André Zo Andrianirina; Sandrine Duron; Marie-José Simon-Ghediri; Lova Ramparany; Annick Lalaina Robinson; Rosa Tsifiregna; Frédérique Randrianirina; Elisoa Ratsima; Josette Raymond; Patrick Imbert

Collaboration


Dive into the Elisoa Ratsima's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Josette Raymond

Paris Descartes University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge